Reports Q2 revenue $3.58M, consensus $1.8M. “We made good progress in executing our strategy in the second quarter, driving towards our goal of nominating our first in vivo development candidate, which we plan to select in September,” said Gilmore O’Neill, president and CEO of Editas Medicine (EDIT). “We are on track to file an IND for our lead program by mid-2026 and achieve human proof-of-concept by the end of 2026. In addition, we announced new proof-of-concept preclinical data for our in vivo programs during the second quarter, which we believe support the potential of our LNP platform and differentiated upregulation strategy to transform the future of disease treatment through gene editing.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.